FDA advisory committee deadlocks on delavirdine. Food and Drug Administration.
Mascolini
M
M
D000998:Antiviral Agents / Q000008:administration & dosage; D018791:CD4 Lymphocyte Count / Q000187:drug effects*; D002986:Clinical Trials as Topic; D020008:Delavirdine; D016049:Didanosine / Q000008:administration & dosage; D018450:Disease Progression; D017277:Drug Approval; D004345:Drug Industry; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D010879:Piperazines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D014481:United States; D014486:United States Food and Drug Administration; D019562:Viral Load; D015215:Zidovudine / Q000008:administration & dosage
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D007211:Indoles; D010879:Piperazines; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D020008:Delavirdine; D016049:Didanosine